Navigation Links
Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting
Date:11/29/2007

CAMBRIDGE, England, November 29 /PRNewswire/ -- Astex Therapeutics Ltd. today announced that data on its drug candidates AT9283, AT7519 and AT9311 will be presented at the American Society of Hematology's 49th Annual Meeting and Exposition, 8-11th December 2007, at the Georgia World Congress Center, Atlanta, Georgia.

AT9283 is an inhibitor of the kinases Aurora A, Aurora B, JAK2, BCR-Abl and Flt-3. There is strong evidence for an important role of each of these kinases in the development or progression of a variety of cancers. AT9283 is currently being investigated in three multi-centre clinical trials, including a Phase I/II study in patients with refractory haematological malignancies.

AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs), currently in two multi-centre Phase 1 clinical trials.

AT9311 (also known as NVP-LCQ195) is also an inhibitor of CDKs, but with a pharmacological profile that is markedly different from that of AT7519. Astex is developing AT9311 in collaboration with Novartis.

Astex discovered all of these compounds using its proprietary fragment-based drug discovery platform Pyramid(TM).

"Astex has discovered and is developing a number of products that may have promise in the treatment of a wide range of life-threatening haematological diseases. Together with investigators from the M.D. Anderson Cancer Center and the UAB Comprehensive Cancer Center, we are reporting for the first time that one of these, AT9283, has already shown early signs of clinical efficacy as a single agent in the treatment of advanced refractory AML and CML," said Harren Jhoti, Chief Scientific Officer and Executive Vice President of Astex.

Hagop Kantarjian, Chairman of the Department of Leukemia at M.D. Anderson, Principal Investigator in the Phase I/II study of AT9283, said, "We see preliminary evidence of the anti-leukemic activity of AT9283 at well-tolerated doses in patients with relapsed and refra
'/>"/>

SOURCE Astex Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. KGI Elects Three New Members to Board of Trustees
2. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
3. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
4. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
5. European Union has Three-Speed Healthcare System - Many Countries Lagging in Reform
6. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. Pharmasset to Present at Three Investor Conferences in November 2007
9. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
10. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
11. Gen-Probe to Webcast Three Upcoming Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... concurrent but separate underwritten offerings of 10,000,000 shares of ... of $2.00 per share, for expected gross proceeds of ... Convertible Preferred Stock at a price to the public ... $20 million. Each share of Series A Convertible Preferred ...
(Date:9/18/2014)... group of rare diseases that afflict skeletal growth ... hits at the fetal stage and is caused ... encoding fibroblast growth factor receptor 3 (FGFR3) has ... thanatophoric dysplasia (TD), a skeletal dysplasia that cause ... lethal, and achondroplasia (ACH), which causes stunted growth ...
(Date:9/18/2014)... The quest for the ultimate memory device for computing ... at The City College of New York led by ... exhibit both magnetic and ferroelectric properties. , Combining both ... can occur between them and for the devices that ... Combining these two properties in a single material, however, ...
(Date:9/17/2014)... 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... Ernst & Young LLP ("EY") that it was resigning effective ... delivered to the Company on September 15, 2014 and reported ... PDL has issued the following statement in response ... of inquiries on the reason for the resignation of EY.  ...
Breaking Biology Technology:Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Oxides discovered by CCNY team could advance memory devices 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3
... 26 Amedica Corporation, an,orthopedic implants company focused ... U.S. Food and Drug Administration,has granted 510(k) marketing ... Valeo Pedicle Screw system is a low profile ... aimed at allowing surgeons,greater flexibility in the positioning ...
... (Nasdaq: GNTA ) announced today that the ... Warrell, Jr., will provide a,company overview and update ... Annual Healthcare Conference. Genta,s presentation is scheduled,for Wednesday, ... New York Palace Hotel,New York, NY., The ...
... International Limited, a UK,private company, announces MHRA ... based Phase IIB trial of AIMSPRO(R), its ... cross-over study will seek to,detect a beneficial ... Secondary,Progressive Multiple Sclerosis, following open-label observations over,several ...
Cached Biology Technology:Amedica Receives FDA 510(k) Clearance for Valeo(TM) Pedicle Screw System 2Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference 2Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference 3
(Date:9/18/2014)... A sleep-promoting circuit located deep in the primitive brainstem ... by researchers at Harvard School of Medicine and the ... this is only the second "sleep node" identified in ... necessary and sufficient to produce deep sleep. , Published ... study demonstrates that fully half of all of the ...
(Date:9/18/2014)... a small, icy moon of Uranus, is one of ... solar system. Despite its relatively small size, Miranda appears ... resulted in the formation of at least three remarkable ... , These coronae are visible in Miranda,s southern ... across. Arden corona, the largest, has ridges and troughs ...
(Date:9/18/2014)... New research into the Crimean-Congo hemorrhagic fever virus (CCHFV), ... in humans similar to that caused by Ebolavirus, has ... discovery has the potential to lead to novel targets ... The research, reported in a paper published today in ... scientists at the Texas Biomedical Research Institute and their ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Research milestone in CCHF virus could help identify new treatments 2
... Md. Scientists have provided new details about how ... the blood cells needed for blood clotting. Katsue Suzuki-Inoue, ... Japan, and colleagues have identified for the first time ... a key role in cancer-induced platelet aggregation. These results ...
... the malaria mosquito uses to zero in on its ... an important step toward developing new and improved repellants ... threat of malaria, generally considered the most prevalent life-threatening ... maxillary palp. It is one of three structures extending ...
... has been developed at the Hebrew University Faculty of ... doctoral research at the university, Dr. Orit Bossi succeeded ... process by countering the breakdown of collagen fibers in ... supervision of Zecharia Madar, the Karl Bach Professor ...
Cached Biology News:How cancer spreads by aggregating platelets 2How cancer spreads by aggregating platelets 3Advance in effort to fight malaria by tricking the mosquito's sense of smell 2Advance in effort to fight malaria by tricking the mosquito's sense of smell 3Antioxidant to retard wrinkles discovered by Hebrew University researcher 2
The external laser upgrade for the Molecular Imager FX adds a 635 nm external laser; the 555 nm long pass filter is replaced with a 605 nm band pass filter to distinguish Cy5 from 532 nm excitable dy...
... DNA Kit is designed for fast and ... plant cells and tissues. The bead beating ... DNA isolation procedures such as CTAB, phenol, ... alcohol precipitation is not necessary - purified ...
The filter 530DF28 for the Molecular Imager FX is a band pass filter for ECL Plus, AttoPhos, SYBR Green, Alexa Fluor 488, FITC, Cy2, and Pro-Q Emerald dyes....
... is a single-step staining method for labeling ... flow cytometry. The kit contains all the ... cells including: positive and negative control cells ... rinsing buffers for processing individual steps in ...
Biology Products: